Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA-KIDNEY Kids
2024-512577-27-00Phase 3Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in chronic kidney disease (CKD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Change in urinary albumin-to-creatinine ratio and Change in urine glucose. Planned start Dec 2025; status: authorised.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-512577-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512577-27-00.